BLISSGVS

Bliss GVS Pharma Financial Results

₹682.00+0.82%
Market cap
₹7,215 crore
P/E
53.0
P/B
6.05
ROE
11.5%
Dividend yield
0.15%

For the year ended Mar 2019, Bliss GVS Pharma reported revenue of ₹898 crore and net profit of ₹127 crore, against ₹689 crore and ₹95 crore a year earlier.

Bliss GVS Pharma annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Bliss GVS Pharma annual profit and loss (₹ crore)
ItemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue8986895777477477668029211,005
Expenses741566471629628605675728818
Operating profit158123107118119161127193187
Operating margin %18%18%18%16%16%21%16%21%19%
Other income382420-429-12343457
Interest456536647
Depreciation91317171926293335
Profit before tax18212910454106117126190202
Tax %30%26%29%57%28%30%28%29%30%
Net profit127957423778290135142
EPS (₹)12.849.346.581.446.807.218.0012.2112.87
Dividend payout %—————————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Bliss GVS Pharma financial results — frequently asked questions

What is Bliss GVS Pharma's annual revenue and net profit?

For the financial year ended Mar 2019, Bliss GVS Pharma's revenue was ₹898 crore and net profit ₹127 crore; net profit rose 33.68% from ₹95 crore in Mar 2020.

How fast has Bliss GVS Pharma grown over three years?

From Mar 2022 to Mar 2019, Bliss GVS Pharma's revenue grew at a compound annual rate of 6.3% and net profit at 76.7%. Past growth does not indicate future results.

What is the EPS of Bliss GVS Pharma?

Annual EPS for Mar 2019 was ₹12.84.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Bliss GVS Pharma With ATS

Track BLISSGVS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.